文献速递慢阻肺呼吸道感染

GLP-1受体激动剂或可改善慢阻肺患者心肺结局

Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD.
PubMed 文献 · Thorax · 2024-10-16

基于台湾全民健康保险研究数据库的纵向队列研究,匹配8060例合并2型糖尿病的慢阻肺患者,比较使用与未使用GLP-1受体激动剂的心肺结局和死亡风险。结果显示GLP-1受体激动剂使用者全因死亡、心血管事件、无创及有创通气、细菌性肺炎风险均显著低于未使用者。

要点

  • 合并2型糖尿病的慢阻肺患者使用GLP-1受体激动剂与较低全因死亡风险相关(aHR 0.46)。
  • GLP-1受体激动剂使用者心血管事件、有创及无创通气、细菌性肺炎风险均显著降低。
  • 亚组及用药时长分析结果一致,提示GLP-1受体激动剂可能有助于慢阻肺合并糖尿病管理。

核心结论

  • 在合并2型糖尿病和慢阻肺的患者中,使用GLP-1受体激动剂较未使用者心肺结局及全因死亡风险更低。

研究设计与样本

  • 采用Cox比例风险模型比较两组心肺结局风险。

主要发现

  • GLP-1受体激动剂使用者平均随访2.51年,非使用者平均随访2.46年。
  • 匹配队列中,GLP-1受体激动剂使用者全因死亡风险显著低于非使用者(aHR 0.46,95%CI 0.38至0.56)。
  • 心血管事件风险显著降低(aHR 0.73,95%CI 0.65至0.82)。
  • 无创正压通气风险显著降低(aHR 0.66,95%CI 0.47至0.93),有创机械通气风险显著降低(aHR 0.64,95%CI 0.51至0.8)。
  • 细菌性肺炎风险显著降低(aHR 0.76,95%CI 0.65至0.88)。

临床怎么用

  • 对于合并2型糖尿病的慢阻肺患者,GLP-1受体激动剂可能作为降糖治疗选择之一,并可能带来心肺结局获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects on cardiopulmonary function. We conducted this longitudinal cohort study to compare the risk of cardiopulmonary outcomes and mortality between GLP-1 RA use and no use in patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disease (COPD). METHODS: The study identified 8060 matched GLP-1 RA users and non-users from Taiwan's National Health Insurance Research Database from 1 January 2008 to 31 December 2019. Cox proportional hazards models were used to determine the risk of cardiopulmonary outcomes between GLP-1 RA users and non-users. RESULTS: The mean follow-up time was 2.51 and 2.46 years for GLP-1 RA users and non-users, respectively. In the matched cohorts, GLP-1 RA users had a significantly lower risk of mortality (adjusted HR (aHR) 0.46, 95% CI 0.38 to 0.56), cardiovascular events (aHR 0.73, 95% CI 0.65 to 0.82), non-invasive positive pressure ventilation (aHR 0.66, 95% CI 0.47 to 0.93), invasive mechanical ventilation (aHR 0.64, 95% CI 0.51 to 0.8) and bacterial pneumonia (aHR 0.76, 95% CI 0.65 to 0.88) than GLP-1 RA non-users. The subsequent analyses for various subgroup and medication duration also showed that GLP-1 RA was associated with a significantly lower risk of mortality, cardiovascular events, ventilation support and bacterial pneumonia than non-GLP-1 RA. CONCLUSION: This nationwide cohort study showed that GLP-1 RA had a lower risk of cardiopulmonary outcomes and all-cause mortality than non-GLP-1 RA in patients with T2D and COPD. GLP-1 RA may help manage diabetes in people with COPD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Yen FS, Hsu CC, Wei JC, et al. Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD. Thorax. 2024. PMID: 39353727. doi:10.1136/thorax-2023-221040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。